Welcome boost to fatigue research
July 02, 2020
Stroke Foundation has welcomed the announcement of a million dollar boost to help find a treatment for fatigue in stroke survivors.
Funded by the Medical Research Future Fund (MRFF), a specialist team from across Australia and the UK will further explore the use of a common drug used to treat sleep disorders in the long-term recovery of people who experience a stroke. In 2016, Stroke Foundation provided a $50,000 seed funding grant for research on ‘Modafinil in Debilitating fatigue After Stroke (MIDAS)’; the results of which have helped see this trial come to fruition.
Stroke Foundation Research Advisory Committee Chair Professor Amanda Thrift said the trial was a testament to the importance of Stroke Foundation’s pioneering research program.
“Research takes a great deal of time and funding; it is heartening to see this trial take flight,” Professor Thrift said.
“Researchers are now one step closer to finding a treatment for fatigue in people following their stroke. Such a treatment has the potential to benefit and improve the quality of life for so many.
“Stroke Foundation is proud to have contributed to the inception of this significant trial.”
More than 56,000 strokes will be experienced in Australia this year alone and there are more 475,000 survivors of stroke living in the Australian community.
Up to 70 percent of people with stroke will also experience fatigue that is not improved by any amount of rest.
Stroke Foundation Chief Executive Officer Sharon McGowan said the trial would provide hope to the many living with the impact of stroke burdened by fatigue.
“Fatigue is often a less visible effect of stroke, but can be debilitating for so many survivors,” Ms McGowan said.
“This research could transform the lives of so many survivors whose daily activities are impacted by fatigue.
“Stroke Foundation is steadfast in its mission to prevent stroke, save lives and enhance recovery and we are proud to support researchers whose work goes on to make an enormous difference.”
Funded by the Medical Research Future Fund (MRFF), a specialist team from across Australia and the UK will further explore the use of a common drug used to treat sleep disorders in the long-term recovery of people who experience a stroke. In 2016, Stroke Foundation provided a $50,000 seed funding grant for research on ‘Modafinil in Debilitating fatigue After Stroke (MIDAS)’; the results of which have helped see this trial come to fruition.
Stroke Foundation Research Advisory Committee Chair Professor Amanda Thrift said the trial was a testament to the importance of Stroke Foundation’s pioneering research program.
“Research takes a great deal of time and funding; it is heartening to see this trial take flight,” Professor Thrift said.
“Researchers are now one step closer to finding a treatment for fatigue in people following their stroke. Such a treatment has the potential to benefit and improve the quality of life for so many.
“Stroke Foundation is proud to have contributed to the inception of this significant trial.”
More than 56,000 strokes will be experienced in Australia this year alone and there are more 475,000 survivors of stroke living in the Australian community.
Up to 70 percent of people with stroke will also experience fatigue that is not improved by any amount of rest.
Stroke Foundation Chief Executive Officer Sharon McGowan said the trial would provide hope to the many living with the impact of stroke burdened by fatigue.
“Fatigue is often a less visible effect of stroke, but can be debilitating for so many survivors,” Ms McGowan said.
“This research could transform the lives of so many survivors whose daily activities are impacted by fatigue.
“Stroke Foundation is steadfast in its mission to prevent stroke, save lives and enhance recovery and we are proud to support researchers whose work goes on to make an enormous difference.”